Should I Buy Tate & Lyle?

LONDON -- It's time to go shopping for shares again, but where to start? There are loads of great stocks to choose from, and I've got my wallet out. So here's the question I'm asking right now. Should I buy Tate & Lyle  (LSE: TATE  ) ?

Sugar, sugar
I've always had a sweet tooth, so why go right to the source of my addiction, and buy Tate & Lyle? It works in the sweetest business of all, sugar, sweeteners, starches, and sugar refining. Sugar consumption has tripled in the last 50 years and we now eat on average 20 teaspoons a day, so I know I'm not alone in my addiction. In fact, we're probably more addicted to the white stuff than alcohol, cigarettes, and sundry illicit substances. Thankfully, sugar is a legal high, freely available on every high street, and even children can buy it. So should I sink my teeth into Tate & Lyle?

A many Splenda thing
Tate & Lyle's share price performance over the past six months couldn't have been sweeter. The stock rose 22% to 7.94 pounds, despite reporting a 26% drop in operating profits for the six months to the end of September 2012. Management blamed that on softer market conditions in Europe and a "step change" in fixed costs, following the restart of its Splenda Sucralose facility in McIntosh, Alabama. Costs may have risen, but revenues remained strong, up 7% to 1.63 billion pounds.

Sweet and sour
The sweeteners and food products group's latest interim management statement, released on Feb. 1, didn't go down as nicely. It warned of a drop in third-quarter profits, which may have been in line with expectations, but still knocked 4% off the share price. Tate & Lyle has been hit by volatile corn prices and last year's hot summer, in which corn fungus aflatoxin flourished. It did report a solid start to the final quarter, but that didn't stop a number of analysts reviewing their hold recommendations. Management said it expected to make "modest progress" this financial year, but the market viewed that as a downgrade on previous claims of unqualified "progress." All that is sugar isn't necessarily sweet.

Modesty forbids
The market still has a taste for Tate & Lyle's products, though the stock is trading at a price-to-earnings ratio of 14.4 times earnings. That doesn't look great value to me, given modest earnings-per-share growth, forecast to be -2% in the 12 months to March 31, 2013, followed by 8% a year for the two subsequent years. The stock currently yields 3.1%, which again looks modest, with the FTSE 100 as a whole yielding 3.5%. I'm not exactly licking my lips at these numbers. Anyway, it's about time I kicked the sugar habit.

You've got the power
There are much better yields to be had on the FTSE 100, including one great low-volatility stock that gives you an income of 5.7% a year. If you want to know what it is, simply download our free Motley Fool guide "Power Up Your Portfolio.

We have picked out this stock because it offers one of the best yields on the FTSE 100, almost three times as much as you can get on cash. The report is completely free, so download it now.

link


Read/Post Comments (2) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 04, 2013, at 9:25 PM, plj101 wrote:

    Tate & Lyle no longer refine sugar. They sold that business a couple of years back.

  • Report this Comment On February 06, 2013, at 3:56 PM, monosabio wrote:

    Right. Tate and Lyle has gotten out of the commodity sugar business and moved to the specialty sweetner market with Sucralose and HFCS. Higher margins and emerging opportunity. Watch where they make new investments. One possability is SNMX. Senomyx has developed modifiers for sucralose and HFCS that allow food and beverage companies to reduce sucralose in their products by 75% and reduce HFCS by 35 % without changiong the taste of their products.The sucralose modifier has just received european market approval and will be available in the market place this year, while the HFCS is awaiting GRAS approval in the USA.. SNMX has >$40million in cash, no debt,and could be a great partner with Tate & Lyle going forward. If you are looking for a stock in this space SNMX is in an excellent position to increase shareholder value.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2231406, ~/Articles/ArticleHandler.aspx, 11/27/2014 4:30:34 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement